VIP vs MOTS-c
Side-by-side comparison of key properties, dosing, and research.
- Summary
- VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Half-Life
- ~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
- Estimated 1–2 hours
- Admin Route
- Intranasal, SubQ, IV
- SubQ
- Research
- —
- —
- Typical Dose
- 50 mcg (4 sprays of 12.5 mcg each)
- 5–15 mg
- Frequency
- 4x daily
- 3–5 times per week
- Key Benefits
- Potent anti-inflammatory for CIRS and mold illness
- Improves pulmonary hypertension symptoms
- Regulates gut motility and IBS symptoms
- Modulates circadian rhythm and sleep quality
- Reduces mast cell activation (MCAS)
- Improves cognitive function in neuroinflammatory conditions
- Vasodilatory — reduces vascular resistance
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Side Effects
- Facial flushing (transient, intranasal)
- Mild nausea
- Headache at initiation
- Hypotension at high doses
- +1 more
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Stacks With
- —
- —